Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.53 |
| ▸ | F11 | P03951 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL28602416 | 0.89 | LIPG (0.49) | LPLLIPGF11CA1CA2 | |
| SCHEMBL1372253 | 0.88 | LIPG (0.67) | LPLLIPGF11CA1CA2 | |
| SCHEMBL30381735 | 0.86 | LPL (0.46) | LPLLIPGF11CA1CA2 | |
| SCHEMBL3517704 | 0.83 | LIPG (0.67) | LPLLIPGF11CA1CA2 | |
| SCHEMBL19489213 | 0.83 | LPL (0.45) | LPLLIPGF11CA1CA2 | |
| SCHEMBL18123774 | 0.83 | CA1 (0.51) | LPLLIPGF11CA1CA2 | |
| SCHEMBL228212 | 0.83 | LPL (0.71) | LPLLIPGF11CA1CA2 | |
| SCHEMBL15803153 | 0.81 | LIPG (0.49) | LPLLIPGF11CA1CA2 | |
| SCHEMBL25981590 | 0.80 | LPL (0.47) | LPLLIPGF11CA1CA2 | |
| SCHEMBL27905476 | 0.79 | LPL (0.36) | LPLLIPGF11CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112375089-A | Photosensitizer with high singlet oxygen yield and preparation method thereof | 山东大学 | 2021-02-19 | — | — | CN | claimed |
| CN-106532120-A | Non-aqueous electrolyte and lithium secondary battery of using same | 广州天赐高新材料股份有限公司 | 2017-03-22 | — | — | CN | claimed |
| EP-4743455-A1 | SARM1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4105216-B1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260132122-A1 | 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS | INCYTE CORP (US) | 2026-05-14 | — | — | US | disclosed |
| US-12617797-B2 | Substituted pyrazolo [1,5-a]pyrimidines having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2026-05-05 | — | — | US | disclosed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-12606558-B2 | Condensed pyrazole derivatives as inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4713095-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | Chengdu Anticancer Bioscience, Ltd. (CN) | 2026-03-25 | — | — | EP | disclosed |
| US-20260071117-A1 | FUNABLE FLUORESCENT COMPOUNDS AND USES THEREOF | UNIV ARIZONA (US) | 2026-03-12 | — | — | US | disclosed |
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | TRIANA BIOMEDICINES, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| US-20040023963-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | CAO JINGRONG (US) | 2004-02-05 | — | — | US | disclosed |
| US-6642227-B2 | Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents | VERTEX PHARMACEUTICALS INCORPORATED | 2003-11-04 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030096816-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| WO-2002096913-A1 | SUBSTITUTED DI(HYDROXY/ALKOXY)SILICON PHTHALOCYANINES AND THEIR USES | GENTIAN AS (NO) | 2002-12-05 | — | — | WO | disclosed |
| EP-1238016-A1 | SUBSTITUTED PHTHALOCYANINES AND THEIR PRECURSORS | Gentian AS (NO) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| WO-2001042368-A1 | SUBSTITUTED PHTHALOCYANINES AND THEIR PRECURSORS | GENTIAN AS (NO) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023963-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | LCK, MAPK1, MAP3K1 | LPL 3701/4885LIPG 2802/4885F11 2331/4885 |
| US-12617797-B2 | Substituted pyrazolo [1,5-a]pyrimidines having multimodal activity against pain | SIGMAR1, OPRD1, OPRL1 | LPL 3434/4885LIPG 4125/4885F11 1642/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | LPL 856/4885LIPG 1084/4885F11 4397/4885 |
| US-12606558-B2 | Condensed pyrazole derivatives as inhibitors of SARM1 | SARM1, SMN1; SMN2, PMP22 | LPL 3342/4885LIPG 2573/4885F11 2574/4885 |
| US-20260132122-A1 | 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS | CCNA1, CDK4, CCNO | LPL 3977/4885LIPG 4600/4885F11 3453/4885 |
| US-20260071117-A1 | FUNABLE FLUORESCENT COMPOUNDS AND USES THEREOF | H1-3, NISCH, H1-2 | LPL 4720/4885LIPG 4824/4885F11 2944/4885 |
| US-20030096816-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | LCK, MAPK1, MAP3K1 | LPL 3701/4885LIPG 2802/4885F11 2331/4885 |
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | ALK, NTRK3, NTRK1 | LPL 742/4885LIPG 1981/4885F11 3058/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | LPL 3899/4885LIPG 4118/4885F11 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.